183 related articles for article (PubMed ID: 11908765)
1. When drugs development meets genomics.
Leung YF; Lam DS; Pang CP
Pharmacogenomics J; 2001; 1(4):237-8. PubMed ID: 11908765
[No Abstract] [Full Text] [Related]
2. Multiple sclerosis: emerging opportunities for therapeutic intervention.
Evans CF; Shriver LP
Curr Drug Targets CNS Neurol Disord; 2002 Feb; 1(1):17-30. PubMed ID: 12769632
[TBL] [Abstract][Full Text] [Related]
3. State-of-the-art genomics approaches in toxicology.
Van Hummelen P; Sasaki J
Mutat Res; 2010 Dec; 705(3):165-71. PubMed ID: 20466069
[TBL] [Abstract][Full Text] [Related]
4. Applying advanced delivery technologies to enable and improve drug development. 8-9 December 2004, London, UK.
Uchegbu IF
IDrugs; 2005 Feb; 8(2):112-4. PubMed ID: 15696410
[No Abstract] [Full Text] [Related]
5. The critical need for cancer biometrics: quantitative, reproducible measures of cancer to define response to therapy.
Lotze MT
Curr Opin Investig Drugs; 2003 Jun; 4(6):649-51. PubMed ID: 12901221
[No Abstract] [Full Text] [Related]
6. Perspective from the founding editors. Preface.
Juliano R; Poste G; Tomlinson E
Adv Drug Deliv Rev; 2013 Jan; 65(1):3-4. PubMed ID: 22940253
[No Abstract] [Full Text] [Related]
7. Anti-infectives in the 21st century.
Clough J
Drug Discov Today; 2002 Oct; 7(20):1036-8. PubMed ID: 12546891
[No Abstract] [Full Text] [Related]
8. Vita Genomics, Inc.
Shih-Hsin Wu L; Su CL; Chen E
Pharmacogenomics; 2007 Jun; 8(6):669-73. PubMed ID: 17559355
[TBL] [Abstract][Full Text] [Related]
9. The impact of systems approaches on biological problems in drug discovery.
Hood L; Perlmutter RM
Nat Biotechnol; 2004 Oct; 22(10):1215-7. PubMed ID: 15470453
[No Abstract] [Full Text] [Related]
10. Drug Delivery Systems--9th US-Japan symposium.
Uhland S
IDrugs; 2008 Mar; 11(3):186-8. PubMed ID: 18311655
[No Abstract] [Full Text] [Related]
11. Value of novelty?
Ma P; Zemmel R
Nat Rev Drug Discov; 2002 Aug; 1(8):571-2. PubMed ID: 12402497
[No Abstract] [Full Text] [Related]
12. Drug Delivery 2007--New technologies, partnering and strategies for the future.
Stevenson L
IDrugs; 2007 Jun; 10(6):388-90. PubMed ID: 17642001
[No Abstract] [Full Text] [Related]
13. Tumor markers: discovery to practice.
Zhang WW
Drug Discov Today; 2003 May; 8(10):441-3. PubMed ID: 12801794
[No Abstract] [Full Text] [Related]
14. Prioritizing the human genome: knowledge management for drug discovery.
Golden JB
Curr Opin Drug Discov Devel; 2003 May; 6(3):310-6. PubMed ID: 12833662
[TBL] [Abstract][Full Text] [Related]
15. Chemical biology and drug design: three-dimensional, dynamic, and mechanistic nature of two multidisciplinary fields.
Sawyer TK
Chem Biol Drug Des; 2006 Mar; 67(3):196-200. PubMed ID: 16611212
[No Abstract] [Full Text] [Related]
16. The journal of pharmacy and pharmacology 2008.
Jones DS
J Pharm Pharmacol; 2009 Jan; 61(1):1-2. PubMed ID: 19126290
[No Abstract] [Full Text] [Related]
17. Pharmaceutical prospects for RNA interference.
Schiffelers RM; Woodle MC; Scaria P
Pharm Res; 2004 Jan; 21(1):1-7. PubMed ID: 14984251
[TBL] [Abstract][Full Text] [Related]
18. Drug discovery and development using chemical genomics.
Sehgal A
Curr Opin Drug Discov Devel; 2002 Jul; 5(4):526-31. PubMed ID: 12197310
[TBL] [Abstract][Full Text] [Related]
19. Molecular targets and cancer therapeutics.
Westwell AD
Drug Discov Today; 2004 Dec; 9(24):1042-4. PubMed ID: 15582792
[No Abstract] [Full Text] [Related]
20. Beyond the genome--SMi Conference 27-28 January 2003, London, UK.
Swinton J; Sheridan JM; Henning SW
IDrugs; 2003 Mar; 6(3):203-6. PubMed ID: 12838986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
